Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets
Immunovant, Inc. (NASDAQ: IMVT) stock is closing out the week in focus after the company completed a major equity raise designed to bolster funding for its autoimmune pipeline—while its controlling shareholder, Roivant Sciences, stepped in as the largest buyer. As of the most recent market close ahead of Sunday, December 14, 2025, IMVT shares were around $26.42, up about 6.6% on the day, following heightened volatility and elevated trading activity during the week. Below is what changed, why it matters for investors tracking Immunovant stock, and how Wall Street-style consensus forecasts currently frame upside vs. risk. What’s driving Immunovant stock